PL3743106T3 - Szczepionki przeciwko wirusowi grypy i ich zastosowanie - Google Patents

Szczepionki przeciwko wirusowi grypy i ich zastosowanie

Info

Publication number
PL3743106T3
PL3743106T3 PL19701815.3T PL19701815T PL3743106T3 PL 3743106 T3 PL3743106 T3 PL 3743106T3 PL 19701815 T PL19701815 T PL 19701815T PL 3743106 T3 PL3743106 T3 PL 3743106T3
Authority
PL
Poland
Prior art keywords
influenza virus
virus vaccines
vaccines
influenza
virus
Prior art date
Application number
PL19701815.3T
Other languages
English (en)
Inventor
Ferdinand Jacobus MILDER
Tina RITSCHEL
Boerries BRANDENBURG
Mandy Antonia Catharina Jongeneelen
Daphné TRUAN
Johannes Petrus Maria Langedijk
Original Assignee
Janssen Vaccines & Prevention B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention B.V. filed Critical Janssen Vaccines & Prevention B.V.
Publication of PL3743106T3 publication Critical patent/PL3743106T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL19701815.3T 2018-01-23 2019-01-22 Szczepionki przeciwko wirusowi grypy i ich zastosowanie PL3743106T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18152991 2018-01-23
PCT/EP2019/051532 WO2019145310A1 (en) 2018-01-23 2019-01-22 Influenza virus vaccines and uses thereof

Publications (1)

Publication Number Publication Date
PL3743106T3 true PL3743106T3 (pl) 2022-11-14

Family

ID=61094216

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19701815.3T PL3743106T3 (pl) 2018-01-23 2019-01-22 Szczepionki przeciwko wirusowi grypy i ich zastosowanie

Country Status (29)

Country Link
US (2) US11447526B2 (pl)
EP (2) EP3743106B1 (pl)
JP (1) JP7317047B2 (pl)
KR (1) KR102777000B1 (pl)
CN (1) CN111655284B (pl)
AU (1) AU2019212180B2 (pl)
BR (1) BR112020014343A2 (pl)
CA (1) CA3089177A1 (pl)
CL (1) CL2020001901A1 (pl)
CY (1) CY1125681T1 (pl)
DK (1) DK3743106T3 (pl)
EA (1) EA202091769A1 (pl)
ES (1) ES2926243T3 (pl)
HR (1) HRP20220980T1 (pl)
HU (1) HUE059545T2 (pl)
IL (2) IL294797B2 (pl)
LT (1) LT3743106T (pl)
MX (1) MX2020007777A (pl)
MY (1) MY200841A (pl)
PE (1) PE20210651A1 (pl)
PH (1) PH12020500569A1 (pl)
PL (1) PL3743106T3 (pl)
PT (1) PT3743106T (pl)
RS (1) RS63526B1 (pl)
SG (1) SG11202006399VA (pl)
SI (1) SI3743106T1 (pl)
SM (1) SMT202200354T1 (pl)
WO (1) WO2019145310A1 (pl)
ZA (1) ZA202004538B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7865873B2 (ja) * 2019-09-05 2026-05-26 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
CN115038713A (zh) * 2019-10-15 2022-09-09 扬森疫苗与预防公司 流感病毒疫苗及其用途
WO2021249013A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Vaccine compositions, methods, and uses thereof
JP2023166633A (ja) * 2020-09-30 2023-11-22 キリンホールディングス株式会社 インフルエンザウイルス抑制用の融合タンパク質およびこれを含む医薬組成物
CN114891074B (zh) * 2022-05-10 2023-04-11 中山大学·深圳 一种季节性甲型流感通用病毒样颗粒及其制备方法与应用
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
GB202219228D0 (en) * 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2024249801A2 (en) * 2023-06-02 2024-12-05 The Scripps Research Institute Influenza estem immunogens
WO2026052773A1 (en) * 2024-09-06 2026-03-12 Sanofi Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
EP0784690B1 (en) 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
CA2731686C (en) * 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
KR101790354B1 (ko) * 2009-05-11 2017-10-25 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 h3n2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도
WO2011123495A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
EP2731967B1 (en) 2011-07-14 2016-10-12 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
IN2014CN04742A (pl) 2011-11-28 2015-09-18 Crucell Holland Bv
CN105452270B (zh) * 2013-05-30 2020-12-01 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
JP6704849B2 (ja) * 2013-08-03 2020-06-03 アバター・メディカル・エルエルシー インフルエンザヘマグルチニンタンパク質およびその方法
WO2016005480A1 (en) 2014-07-10 2016-01-14 Crucell Holland B.V. Influenza virus vaccines and uses thereof
KR102463632B1 (ko) * 2014-07-10 2022-11-03 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도

Also Published As

Publication number Publication date
SMT202200354T1 (it) 2022-09-14
SI3743106T1 (sl) 2022-10-28
EP4119154A1 (en) 2023-01-18
BR112020014343A2 (pt) 2020-12-08
KR102777000B1 (ko) 2025-03-10
MX2020007777A (es) 2020-09-18
AU2019212180B2 (en) 2025-04-03
EA202091769A1 (ru) 2020-10-16
US20200377555A1 (en) 2020-12-03
HRP20220980T1 (hr) 2022-11-11
JP7317047B2 (ja) 2023-07-28
IL275849B (en) 2022-09-01
US20220411474A1 (en) 2022-12-29
IL294797B1 (en) 2024-02-01
IL294797A (en) 2022-09-01
AU2019212180A1 (en) 2020-07-16
EP3743106A1 (en) 2020-12-02
MY200841A (en) 2024-01-18
PH12020500569A1 (en) 2021-05-10
LT3743106T (lt) 2022-09-26
CA3089177A1 (en) 2019-08-01
IL275849A (en) 2020-08-31
HUE059545T2 (hu) 2022-11-28
CY1125681T1 (el) 2026-02-25
CN111655284A (zh) 2020-09-11
PT3743106T (pt) 2022-08-24
DK3743106T3 (da) 2022-09-05
RS63526B1 (sr) 2022-09-30
EP3743106B1 (en) 2022-06-15
IL294797B2 (en) 2024-06-01
CL2020001901A1 (es) 2020-10-23
JP2021511077A (ja) 2021-05-06
ES2926243T3 (es) 2022-10-24
PE20210651A1 (es) 2021-03-26
KR20200113226A (ko) 2020-10-06
US11905314B2 (en) 2024-02-20
WO2019145310A1 (en) 2019-08-01
ZA202004538B (en) 2023-01-25
CN111655284B (zh) 2024-06-11
SG11202006399VA (en) 2020-08-28
US11447526B2 (en) 2022-09-20

Similar Documents

Publication Publication Date Title
ZA202004538B (en) Influenza virus vaccines and uses thereof
ZA201700165B (en) Influenza virus vaccines and uses thereof
SG11201610443WA (en) Influenza virus vaccines and uses thereof
SG10201913630YA (en) Zika virus vaccine
EP3364983A4 (en) VACCINES AGAINST RESPIRATORY VIRUSES
IL275427A (en) Hepatitis virus vaccines HBV) B) and their uses
GB201613191D0 (en) Zika virus vaccine
IL263550A (en) Infectious bronchitis virus vaccine
IL279726A (en) The hemagglutinin mutants of the influenza virus
EP3334833A4 (en) RECOMBINANT TURKEY HERPESVIRUS VACCINES AND USES THEREOF
IL262731A (en) Therapeutic hpv vaccine combinations
PT3800257T (pt) Agentes pan-genotípicos contra o vírus influenza e métodos de utilização dos mesmos
EP3240568A4 (en) Recombinant influenza virus vaccines for influenza and respiratory syncytial virus
GB201702193D0 (en) Hepatitis E virus vaccine
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
HK40079962A (en) Influenza virus vaccines and uses thereof
HK40078791A (en) Influenza virus vaccines and uses thereof
HK40064394A (en) Nanoparticle-based influenza virus vaccines and uses thereof
IL249705A0 (en) Influenza virus vaccines and their uses
IL249704A0 (en) Influenza virus vaccines and their uses
HK1236965A1 (en) Influenza virus vaccines and uses thereof
GB201808500D0 (en) Virus and virus use
AU2018903913A0 (en) Virus Vaccine
HK40019937A (en) Broad spectrum influenza virus vaccine
HK40020006A (en) Influenza b virus mutants and uses therefor